Navigation Links
Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
Date:11/12/2013

NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Richard I. Steinhart to its board of directors (Board). The Board also named Mr. Steinhart as Chairman of the Board's Audit Committee and a member of the Board's Compensation Committee.

The Company's Chief Executive Officer, Dr. Kaushik Dave, said, "We are very pleased to have Richard join our Board. His financial and industry expertise complements our current, experienced Board members.  He will add valuable knowledge and guidance as we expand and develop our product pipeline."

"It's a great pleasure to be joining the Board of Actinium and to have the opportunity to work with a talented team focused on developing treatments for unmet medical needs in cancer," said Mr. Steinhart.

Mr. Steinhart has been employed by MELA Sciences, Inc, as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary since April 2006 and in April 2012, Mr. Steinhart received a promotion to Sr. Vice President, Finance. From May 1992 until joining the MELA Sciences Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart's other experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, Mr. Steinhart served on the Board of Manhattan Pha
'/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
7. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: ... pharmaceutical company with the largest cardio-cerebral vascular ("CCV") ... prescription drug market, today announced the unaudited consolidated ... the "Group") for the six months ended 30 ... the Six months ended 30 JuneKey Income Statement ...
(Date:8/27/2014)... N.C. , Aug. 27, 2014 Kewaunee ... its Board of Directors increased its quarterly cash dividend ... eleven cents per outstanding share, beginning with the dividend ... at the close of business on September 8, 2014. ... Founded in 1906, Kewaunee Scientific Corporation is a ...
(Date:8/27/2014)... THOUSAND OAKS, Calif. , Aug. 27, 2014 /PRNewswire/ ... the U.S. Food and Drug Administration (FDA) has granted ... chronic heart failure (HF). Ivabradine is an oral drug ... ("funny" current) in the sinoatrial node, the body,s cardiac ... rate without negative effects on myocardial contractility or ventricular ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... 20, 2011 Chembio Diagnostics, Inc. (OTC/QB: CEMI & ... diagnostic tests, announced today that the Company will release ... the open of the market on Thursday, November 3, ... be available immediately after 9:15 a.m. on our web ...
... Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... 30, 2011, on Thursday, October 27, 2011, after the markets close. ... Time to discuss the financial results and provide an update on ... To access the live conference call on October 27, ...
Cached Medicine Technology:Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results 2Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results 3Cardica to Announce Fiscal 2012 First Quarter Financial Results on Thursday, October 27, 2011 2
(Date:8/27/2014)... (PRWEB) August 27, 2014 For nearly ... performances by the beloved mantra singers Deva Premal & ... Following the release of their latest album in May, ... down in twenty-two countries around the globe, including Russia, ... Argentina and across Europe. With a new album and ...
(Date:8/27/2014)... positive hospital blood culture samples are discarded every day ... skin germs instead of specific disease-causing bacteria. , ... clinicians may be able to use the resistance profiles ... patients with antibiotics appropriate to their ailment, Tel Aviv ... Alon of TAU,s Sackler Faculty of Medicine and the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According ... Market Research "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, ... Electrical, Ultrasound, Microwave, Cryotherapy) - Global Industry Analysis, ... 2020," the global ablation technologies market was valued ... estimated to reach a market worth USD 10,611 ...
(Date:8/27/2014)... and tested an advanced statistical model to evaluate ... disease as published yesterday in Human Genetics ... gap in current analyses. Complex diseases like cancer ... environmental factors. When many such combinations are studied, ... chance combinations among affected individuals becomes difficult. In ...
(Date:8/27/2014)... August 27, 2014 Nava Beauty Store and ... to all patrons from those seeking luxury care products to ... They carry high end luxurious brands like Valmont and Elemis ... also sells brands like Dermalogica and Bliss to provide easy ... customers. They also offer purely organic skin care products such ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:'Junk' blood tests may offer life-saving information 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2
... conducted among about 200 people with multiple sclerosis ( ... such as pain, tiredness,// emotional well-being, vitality, social functioning, ... living. Results from the MS patients were then compared ... the general population. ,Multiple sclerosis patients in the ...
... help doctors identify which postmenopausal women are at an ... most important// predictor of bone fracture in postmenopausal women ... mineral density is measured by a T-score. As the ... has been what level of a T-score indicates an ...
... standards for measuring blood pressure in children based on age, ... children as young as age 3 should receive regular blood ... percentile for blood pressure are diagnosed with high blood pressure. ... are said to have pre-hypertension -- a relatively new classification ...
... population carries a gene that puts them at risk for ... offspring.// Researchers say they already know one form of the ... to neural tube defects. They speculated another form of the ... ,Researchers studied about 400 people with neural tube defects, comparing ...
... 1 million cases of skin cancer are diagnosed. More than ... more than 7,000 people die yearly. Now, doctors are using ... some patients. ,Mary Louise Gramkow spent her life in ... sort of thing. [I am] just an outdoor person.” All ...
... worn by medical staff carry disease-causing bacteria. Researchers sampled ... and security personnel at a teaching hospital. Their data ... by the medical staff were contaminated with bacteria. ... transfer disease to patients, it is a good opportunity ...
Cached Medicine News:
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: